#13 - Roger Frechette, Co-Founder & Principal at New England PharmAssociates
Épisode 13
mercredi 5 octobre 2022 • Durée 37:32
Joining Slice of Life Sciences Real Estate today is Roger Frechette who is a life sciences consultant/advisor, helping early-stage life science companies to succeed and to grow. His work with clients leverages an extensive global network and multi-disciplinary insights derived from over 20 years of experience in the business of life sciences, calibrated with an extensive science background.
In this episode you'll learn about:
Frechette’s background
His experience with co-founding a company, and the company’s story
The services New England PharmAssociates specializes in
His role as Vice Chair of Life Sciences for the Boston Entrepreneurs’ Network and the events they put on
Common themes he’s observed over the years from the innovators and companies he has worked with
The primary piece of advice he would give to someone about to start a company in the biotech industry
For more information on New England PharmAssociates please follow this link: - LinkedIn
This podcast is produced by Slice of Media, INC.
#12 - Chris Bahl, Chief Scientific Officer & Co-Founder of AI Proteins
Épisode 12
mercredi 21 septembre 2022 • Durée 23:48
Hi everyone and welcome to episode #12 of Slice of Life Sciences.
We have a great conversation lined up today as we are joined by Chris Bahl, Chief Scientific Officer and Co-Founder of AI Proteins. I have gotten to know Chris this past year, which makes me especially excited to hear about his journey and how it led to this newly founded biotech company focused on the design and engineering of synthetic miniprotein therapeutics.
In this episode you'll learn about:
Bahl's background & what made him want to study protein
How AI Proteins came about
The challenges AI Proteins is solving
The culture of AI Proteins
Milestones they are looking to hit
What Bahl is most excited about for the future of AI Proteins
Advice he would give to aspiring entrepreneurs
For more information on AI Proteins please follow these links: - Website - LinkedIn
This podcast is produced by Slice of Media, INC.
#3 - Mark Tebbe, Entrepreneur in Residence at Atlas Venture
Épisode 3
mercredi 30 mars 2022 • Durée 48:54
Introduction:
Welcome to the third episode of Slice of Life Sciences…This week we will take our conversation from the Life Science real estate industry and focus more so on the ins and outs of managing and running a biotech company. Without further ado, Mark Tebbe, Entrepreneur in Residence for Atlas Venture, whom has had an illustrious career as a serial entrepreneur focusing on drug discovery and management in biotech/pharmaceutical industry with a broad experience involving drug development, operations, and international assignments. Mark has worked as both a consultant and full time at multiple biotechs including 3 years as co-founder and Chief Technology Officer at Quench Bio focused on severe inflammatory diseases, 3 years at Quartet Medicine as head of drug discovery focused on peripheral neuropathic pain, 3 years at Forma Therapeutics as Vice President of Medicinal and Computational chemistry building the group and delivering on a broad portfolio of cancer targets, and many more.
Background:
I always find it interesting to learn about personal / educational background;
Where did you grow up? Who/what were the major influences in your early life?
Did you have a passion early on or did it evolve as you got older?
Where did you go to college and what did you decide to study there? (Notre Dame)
Did you decide get your PhD right after undergrad? (Stanford)
Throughout your years at Notre Dame and Stanford, did you develop relationships with mentors that helped you think about what you wanted to do / what would give you a sense of fulfillment?
Was entrepreneurship an itch you wanted to scratch at a young age or did this come later in your career?
Professional Career:
Your first job after receiving your PhD was at Eli Lilly as an Organic Chemist in the area of Infectious Disease and early on you were chairman of a team of ca. 10 people (PhD’s) responsible for all ID targets and the lead generation strategy taken toward these targets. Were you responsible for the organization of the team as well? What were some take ways / lessons on how to build and lead a team that you took with you later on in your career?
#2 - Daniel Guadagnoli, Director at The Fallon Company
Épisode 2
vendredi 11 février 2022 • Durée 30:50
Introduction:
Dan Guadagnoli, Director of the Fallon Company. The Fallon Company is a privately held commercial real estate owner and developer of transformative, urban mixed-use environments headquartered in Boston, Massachusetts. Since 1993, The Fallon Company has developed over $6 billion in real estate, representing more than six million square feet of property. TFC has grown across the US with offices in Boston, Charlotte, Raleigh, and Nashville.
Background:
Where are you from, where’d you go to school, and what were your personality strengths going into the real world?
How’d you get into the real estate industry and at what age did you know it is what you wanted to do?
Have you always focused on the same market and what’s your focus at TFC? How do you filter through potential development opportunities?
How many different departments does TFC have and is the mission the same throughout the markets i.e. core investments, value-add, opportunistic
The Fallon Company:
TFC has a unique vision in their developments, emphasizing collaboration and respect for the community…What goes into ‘Master Planning’ large scale, urban-mixed use environments? Is each asset in the development ecosystem TFC creates intended to enhance the performance of these assets individually?
Who’s involved from the beginning, outside of just TFC’s team? Local stakeholder’s architects, community groups, public leaders, etc? How does their knowledge and buy in help your team in what you are building?
What does it mean for your neighborhood’s to reach their maximum potential? How important is walkability, amenities, natural/cultural elements, etc? Are you crating a true neighborhood, not just one asset?
Different years have different trends where different types of developments will prosper. How adaptable and flexible are TFC’s views? I imagine it is less reactive and more so being the trailblazer? I say that because everyone talks about lab developments nowadays, but TFC developed the Vertex campus in the Seaport before there was any other lab in the entire submarket….
#1 - Camille White, Senior Associate at BioMed Realty
Épisode 1
jeudi 16 décembre 2021 • Durée 27:11
Introduction:
Camille White, Senior Associate on BioMed Realty’s leasing team, who is a Blackstone portfolio company and leading provider of real estate solutions for the life science industry with over 14M sf worldwide in major markets like Boston, Bay Area, San Diego, Seattle, NY, and UK.
Where’d you go to school and what’d you study?
How did you get in real estate? BioMed?
Did you know you wanted to work in the LS industry in some capacity before joining BioMed?
What’s your favorite part about your job and how does your day-to-day look?
About BMR:
BMR invests in life science and biotech properties in core life science markets.
How important is vertical integration for BMR to get from an idea to managing a fully leased up asset: Leasing, Development, Acquisition, Financing, Asset Management?
What exactly is considered a core life science market and how does BMR view expanding in existing core markets versus being on the forefront of growing a lesser market?
It’s interesting how many players there are that make up a LS ‘cluster’ and the relationships that make a cluster successful: Developer/Landlord, LS asset expertise and adequate capital, tenants (partnership with landlord), Vetting of prospective tenants (financing/due diligence), Amenities/talent attraction and retention….What is BMR’s playbook for identifying an opportunity and turning it into a cluster within a cluster?
What ranges of tenant’s does BMR have in their portfolio? How does your team look at a large pharma company with incredible credit versus a Series B, rapidly growing prospective tenant when leasing up your buildings? Growth is incredibly important to so many LS tenants so how much do large portfolios of assets resonate with tenants in your buildings?
What are some of the obstacles you go through when leasing office/laboratory space to a tenant? It’s not one tour then an immediate lease signing…these are massive amounts of money that BMR is investing in the development, but also in the company who is leasing the space and getting a TI allowance of i.e. $225/sf with a term commitment of 10 years….this creates a very real partnership, does it not?
#11 - Jake Lombardo, Co-Founder & CEO at Anodyne Nanotech
Épisode 11
mercredi 7 septembre 2022 • Durée 33:19
Thanks everybody for joining us on episode #11 of Slice of Life Sciences.
I’m very much looking forward to today’s episode as I am joined by Jake Lombardo, Co-Founder and CEO at Anodyne Nanotech, which is a venture-backed, preclinical-stage biotech company developing differentiated, transdermal forms of high-value drugs.
In this episode you'll learn about:
Lombardo's background
Where he grew up, and how he gained interest in biotech
His mentors that inspired him early on
His time at Union College, and his research projects there
His time at Tufts University’s Gordon Institute to receive a Master of Science in Innovation and Management
The founding of Anodyne Nanotech
the genesis of the company
The problem the Anodyne team is solving and what applications on the world their science/technology can have
The Hero Patch
Pharmaceutical partners that Anodyne is working with
The seed round received last April
What this means for the growth of Anodyne, and what the investment been put towards
The challenges Lombardo has faced with Anodyne Nanotech, and what continues to excite him
How he's juggled hiring, fundraising, and managing a team?
and about being an entrepreneur:
Was there a specific moment Lombardo knew he wanted to be an entrepreneur, or did it happen organically? And
any advice he’d give to another ‘Jake Lombardo’ getting his master’s about to start a company?
Jake, thanks so much for taking the time to chat with us...can’t wait to continue hearing about your
teams’ successes and growth!
This podcast is produced by Slice of Media, INC.
#10 - Arnav Chhabra, Co-Founder at Satellite Bio
Épisode 10
jeudi 14 juillet 2022 • Durée 38:16
Good afternoon everyone and welcome back to Slice Of Life Sciences.
I’ve been super eager to get to today’s session given our guest and what his company has done and is continuing to do as they are pioneering Tissue Therapeutics. I typically like you give an overview of the person and company, but today I am going to keep it short and sweet so we can dive right in. We have Arnav Chhabra, Co-Founder of Satellite Bio with us today, who is working on the next frontier of regenerative medicine which has enormous potential to solve some of the most elusive diseases in the world.
Arnav, thanks very, very much for being with us today and allowing the Slice Of listeners to hear about you, your background, and all things Satellite Bio.
What you'll learn about Chhabra:
Chhabra's background
How Chhabra became interested in biotech and who inspired him
Chhabra's experience at UT and what his focus of study was
How Chhabra's projects were able to become funded by the National Science Foundation and how he also became a member of the Forbes 30 under 30 list.
Mentors at the university that helped Chhabra discover what he wanted to do after he graduated
How Chhabra found himself at MIT and Harvard Medical School pursuing his Postdoc?
What you'll learn about Satellite Bio:
How co-founding Satellite Bio came about, and who was the team that Chhabra had with him
Satellite’s mission
What impacts can Satellite Bio have on people all over the world and, more specifically, describe to us what the impact is that Tissue Therapeutics can have
Their recent funding - and what this money will be used toward
Their focus right now, and the reach this regenerative medicine can have
Chhabra's primary role in the company & it's growth
How the marketplace for Satellite Bio's therapies changed since it started
What excited them the most about the potential of regenerative medicine and what can come from this
The biggest challenges for Satellite Bio, and how important good hiring has been
#9 - Mimi Yen, CEO & Co-Founder at PhagePro
Épisode 9
mercredi 8 juin 2022 • Durée 28:41
In this episode, Mimi Yen, CEO & Co-Founder at PhagePro joins host David Thomann for episode #9 of Slice of Life Sciences Real Estate podcast.
Today makes for another great discussion as we have Mimi Yen, CEO and Co-Founder of PhagePro, which she co-founded in 2016 and is an early-stage biotechnology therapeutics company that develops bacteriophage-based products to help the world’s most vulnerable communities. Mimi has had an impressive journey to where she is and what she is doing today, so I’m excited to dive into together.
What you'll learn about Yen in this episode:
Yen's background and her interests/inspirations growing up
Did you have particular people in your life that got you thinking about what your educational interests were and how you could practice these interests in the real world?
Yen's undergrad experience, and her research studies
Any mentors Yen had that helped her find her path
Her experience at Tufts as a Doctorial Candidate and later a Postdoctoral Research Scholar
At what point did Yen decide that she wanted to build something rather than start off at a larger company?
What you'll learn about the founding of PhagePro:
What was the genesis and how this came about/where Yen met her co-founder
What does PhagePro aim to do and how will the world benefit from the companies’ mission and solutions
Where PhagePro is currently focusing its efforts
What the day to day responsibilities consist of
A few notable successes Yen has had with PhagePro, and what the biggest challengers for the CEO of an early stage company are
What Yen is most looking forward to as she continues building and striving for her goals
What advice would you give someone in your shoes at Tufts who has found their passion and is about to start a company?
This podcast is produced by Slice of Media, INC.
#8 - Bernardo Cervantes, Co-founder at Concerto Biosciences
Épisode 8
mercredi 1 juin 2022 • Durée 29:12
In this episode, Bernardo Cervantes, Co-founder at Concerto Biosciences joins host David Thomann for episode #8 of the Slice of Life Sciences Real Estate podcast.
Bernardo has a Ph.D. from MIT in Microbiology, Microbiome, and Synthetic Biology and then, I believe, jumped immediately into becoming a Co-Founder, unlike some of the other founders we have had on the show. Concerto Biosciences is less than two years old and is unlocking the potential for microbial consortia…we’ll dive into much more about Concerto along with the responsibilities Bernardo has for this fast-paced early-stage company.
What you’ll learn in this episode:
Cervantes’s story/background
Career shaping experiences
Questions we cover about Cervantes:
Where did you grow up, and did you have people or events in your life that inspired the interests you pursued later on in life?
Did you know what you wanted to study when you got to college and at what point did you start knowing what you wanted to do after undergrad?
Did you go straight to MIT after you graduated Cal Berkeley?
Tell us a little bit about some of the publications you had during your time at MIT and any particularly important projects you worked on
Whether at Berkeley or MIT, did you have any mentors that got you thinking about entrepreneurship or how does a young man like you decide to start something rather than, I don’t know, go to a large pharmaceutical company for x amount of years before taking a leap of faith?
What You’ll learn about Concerto Biosciences:
How did Concerto Bio come about, what was the motivation, and who are your co-founders/did you meet at MIT?
For the non-PhDs, what does Concerto do in the simplest of answers?
What is the problem your team is solving and are you the first company to pinpoint microbial ensembles?
What impact will this have on the world or differently put, what are the therapeutic combinations your team is discovering that are benefitting people and what other applications is the future goal?
#7 - Kori Rahaim, Vice President, Head of People 4:59 Initiative at 5AM Ventures
Épisode 7
jeudi 28 avril 2022 • Durée 21:57
Introduction:
Here we are today on episode #7 of Slice of Life Sciences. I am excited to have Kori Rahaim joining me today. Kori is the VP, Head of People at 5AM Ventures and 4:59 NewCo, a 5AM Venture Company.
Outline:
Have you always worked in biotech or what led you to get an opportunity in the field?
At Novartis, you oversaw theHR function for two innovative research organizations, served on two leadership teams, providing coaching to executive leaders. What were some of the program initiatives you put in place to build leadership skills across these organizations?
So, after Novartis you became an early employee at a rapidly growing startup, Relay Therapeutics...This must have been very different in a lot of ways than your previous years in large pharma...what motivated this transition and what are some of the things you learned being the Head of Talent Acquisition as it pertained to recruiting top scientific researchers and G&A talent in a highly competitive biotechnology space?
Are traditional processes something you challenge in relation to what employees think of as a typical HR leader?
What were the most exciting and hardest aspects of growing an early-stage company?
How did you get connected to 5AM Ventures and was having the ability to lead company culture and talent acquisition for multiple companies at once make for a dream opportunity?
Can you talk about 5AM’s strategy when it comes to finding and shaping these new companies?
The earlier stages in a startup’s life are foundational when building a team, you and your team must think deeply about how all the pieces fit together, especially in the early days.Does this put an even larger emphasis on the importance of building out a team than previous roles in
Podcasts Similaires Basées sur le Contenu
Découvrez des podcasts liées à Slice of Life Sciences Real Estate. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !
At Eli Lily you moved to various locations, including, North Carolina and Hamburg Germany, leading chemistry efforts, being directly responsible for overall operations, budget/communication issues across global sites, and redefining site leadership structures; Tell us a bit about how your experiences led you to the major milestones and how your role progressed at Eli Lilly over the years.
After 16 years at the same company, the size of Eli Lilly, with well-rounded exposures, you relocated to Cambridge, MA and joined companies that were much earlier in their lifecycles. How did this move come about?
What were the main differences and challenges you faced with your transition to FORMA and Quatet Medicine? Was the experience working at a large pharma company for so long invaluable for these new endeavors?
The first company you co-founded was then Quench Bio, which was an Atlas portfolio company. You were the Chief Technology Officer for Quench focusing on the chronic aberrant activation of the innate immune system. How did the founding of Quench come about and what was the inspiration? I imagine a whole new set of challenges and lessons came from being an executive and founder so from these 3 years, what is the best advice you would give other biotech founders? Were the similarities in anticipating challenges and being proactive in solutions from your earlier career experiences or did this prove to be a very unique, all around experience?
Taking us to the present, you are an entrepreneur in residence at Atlas Venture while working as a consultant in the pharmaceutical industry to optimize business strategies. We’d love to hear what you are working on and what excites you the most about where you are in your career now.
How large is your current team and what is on the horizon in the coming years?
Is the ability to ‘build’ the most exciting aspect of being an entrepreneur versus working at a large corporation or is something else the main driver for you?
General:
Managing a team and a company must take an incredible amount of trust to hold everyone accountable and keep everyone engaged. What are the best methods of empowering colleagues and attracting/retaining talent that you’ve put to practice?
How do you self-assess throughout the different stages in your career? Have failures been as valuable as successes?
How often to you have dialogues with other industry leaders, mentors, etc. to help you think through challenges and topics that are top of mind for you, whether specific or general?
Personal:
Being a serial entrepreneur, how do you balance your life with your profession?
What do you do during your free time?
How important are the connections and relationships you’ve built throughout your journey in biotech?
If you look back on your career, what is one thing you’d wish you could tell a young, green Mark Tebbe?
Talk to me a little bit about the investment philosophy of your firm. How do you evaluate / manage the risk that any developer goes through and do you take a long-term approach to your investments?
Knowing you have a presence in Boston, Charlotte, Raleigh, and Nashville…, how does your team look at each of the markets? Are you investing in a particular asset class for each?
With so many large biotech companies in the market for new HQs and/or GMP facilities, how does the process work for a ‘build-to-suit’? Do you partner with the client to acquire land in a certain market and what is the timeline for land acquisition, re-zoning, design, GC pricing, and construction for a ground up project?
What’s the difference between a build-to-own versus a build-to-rent? And how much upfront investment would be requirement by a company if they were interested in a build-to-own? Do you share the underwriting and financial models with the client to back into a build-to-rent structure?
With covid’s effects, has anything changed in your philosophy? The great office versus lab debate comes to mind
Case Studies:
In 2005, TFC transformed nine city blocks of abandoned parking lots into, in my opinion, the most vibrant submarket in Greater Boston. What went into attracting Vertex to become Fan Pier’s anchor tenant with two properties totaling 1.1M square feet and was this key in the fantastic, surrounding retail, residential, and restaurant spaces that truly make the area work, live, play?
Fast forward to the present and latest addition, the MassMutual building at 10 Fan Pier, which is a staple office building in the neighborhood. Is an anchor tenant like Vertex or MassMutual common for your various investments?
Looking Forward:
What are some of the things you are working on now?
Is TFC growing in new markets such as Nashville and expanding in more established markets like Boston equally?
What excites you most about looking ahead at the opportunities that you and your teammates are working on / have in the pipeline?
What gives you the most satisfaction from what you and your team do?
I used to think I was in the business of space, but it’s become more apparent to me that I am in the business of people…I say this because the LS is so competitive that companies putting together a real estate strategy will be opening a facility that will need to attract and retain talent when competing with so many other…How important is this to BMR as you evaluate how to construct developments, creation of a community (like mind LS companies), public transportation, proximity to universities, building sustainability, etc?
BioMed is one of the most respected LS real estate provider in the world and knows the ins and outs of what it takes to develop or re-develop a proper lab building…What do you make of so many new ownership groups entering various LS markets to convert traditional office buildings into lab
The LS industry is going through record high activity with funding’s, IPOs, M&A’s, and partnerships…how is this translating into the real estate landscape?
With demand severely outweighing supply, when/if do you think the life science real estate market will slow down?
Recent News:
BMR has been incredibly busy this past year from the $3.45B acquisition of Brookfield’s Cambridge portfolio, to your first Seaport acquisition and redevelopment, to the Assembly Square site in Somerville, to even the doubling of size in BMR’s UK portfolio
What are you most excited about for the future with all of these recent milestones?
I obviously focus primarily on the Greater Boston life science landscape, but what do you see in the broader market? In Greater Boston, for example, the area went through ‘The Kendall Effect’ where LS clusters have grown elsewhere and grown rapidly due to opportunity…are certain markets expanding or are more and more small, LS pockets popping up?
What are the most important pillars to have that make up a successful, major LS cluster?
Scientists cannot do their work without a lab, so knowing that, is that a motivating aspect for you? That you are handling the real estate so your tenant’s can focus on scientific research that can change the world?
Company values that are key components of who Satellite Bio’s team is, & what they're most looking forward to in these next few years
This podcast is produced by Slice of Media, INC.
Lire plus
Réduire
We know you are a Co-Founder, but working at an early stage and growing startup must mean you wear a lot of hats and have many responsibilities…can you share what a day in the life of Bernardo is like?
I know Concerto has only been around since 2020, but what notable successes has your team had? You have been in the news lately, which is exciting.
As you look back on the past ~ 2 years, how has it been being a co-founder right after receiving your Ph.D. and what do you believe are the key tools that make your team and your culture as exciting now as day 1?
What are the biggest challenges a growing and early team like yours faces… Is it as you would have expected?
There are a lot of entrepreneurs who listen to this podcast so I always like to ask two questions, 1) was there a specific moment you knew you wanted to be an entrepreneur? And 2) any advice you’d give to another Ph.D. about starting a company?
This podcast is produced by Slice of Media, INC.
your career?
How do you build a transformative culture when the teams are so early, or in a virtual/hybrid world?
The 4:59 Initiative is super interesting. Can you share what exactly this is and is it specific to certain portfolio companies or is every company part of this?
How long into a company’s life cycle do you assume an operating role and what are the benefits
you’ve seen from this?
How many companies are you typically working on at any given time and what responsibilities does your role cover? Do you have to have an ability to flex across different roles and responsibilities on a regular basis?
Essentially becoming an extension of your portfolio companies’ team make for a lot going on at once, whether, helping set company strategy, management recruiting, business development and fundraising...with that, I imagine each day brings new challenges?
Structurally, what does your department team typically look like?
Did Covid affect the operational process for a life science company with in-house lab? Do you think anything changed for the long-term and not only the short-term?
What excites you most about the journey ahead for you and your team?
